OT-551
- Generic Name
- OT-551
- Drug Type
- Small Molecule
- Chemical Formula
- C13H23NO3
- CAS Number
- 627085-11-4
- Unique Ingredient Identifier
- DZ02S3A31N
- Background
OT-551 is a novel small molecule that is topically dosed in an eye drop and has the unique ability to penetrate cell membranes and reach both the front and the back of the eye. It is intended to treat Age-related macular Degeneration (AMD), and preclinical research results indicate additional uses for OT-551, including treatment of early stage and advanced dry age-related macular degeneration (AMD) by protecting against retina photoreceptor cell death and inhibiting angiogenesis, the growth of small blood vessels leading to the wet-form of AMD. A leading cause of vision loss, AMD affects approximately 10 million Americans.
- Indication
Investigated for use/treatment in cataracts, eye disorders/infections, glaucoma, and macular degeneration.
The OMEGA Study: Use of Eye Drops to Treat Geographic Atrophy Associated With Age-Related Macular Degeneration (Dry AMD)
- First Posted Date
- 2007-06-13
- Last Posted Date
- 2008-04-02
- Lead Sponsor
- Othera Pharmaceuticals
- Target Recruit Count
- 198
- Registration Number
- NCT00485394
Study of OT-551 Eye Drops to Prevent or Delay Progression of Nuclear Cataracts Following Vitreous Removal
- Conditions
- Epiretinal MembraneMacular Hole
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2008-04-02
- Lead Sponsor
- Othera Pharmaceuticals
- Target Recruit Count
- 164
- Registration Number
- NCT00333060
OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration
- Conditions
- Age-Related Macular DegenerationGeographic AtrophyAMD
- Interventions
- First Posted Date
- 2006-03-23
- Last Posted Date
- 2020-07-14
- Target Recruit Count
- 11
- Registration Number
- NCT00306488
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.